ClinicalTrials.gg
CompletedNCT00805441Updated Sep 17, 2019Results posted

A Study in the Treatment of Alcohol Dependence.

A Phase 2 interventional study of LY686017 and Placebo in Alcohol Dependence, sponsored by Eli Lilly and Company. Completed at 21 sites in United States. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-09-17.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
190
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,073 studies in Alcoholism with a site in United States — 187 open to participants now, 227 under way, 15 of them phase 3. Alcoholism · United States.

Enrollment
210th of 989
190 · median 80
Started
2008
with 38 others
Phase 2
247 of 1,073
38 open now
Registered
238th of 1,073
by date

Among the 1,073 studies in Alcoholism with a site in United States, this one is the 210th largest by enrollment of the 989 interventional ones that give a count, is one of 39 that started in 2008, is one of 247 in phase 2, and was the 238th registered.

Alcoholism

1,676 studies on the registry are indexed under Alcoholism; 331 are open to participants now.

Browse Alcoholism studies →

Open to participants now

187 of the 1,073 studies in Alcoholism with a site in United States are open now. Recruiting first, the newest first:

182 more — sign in →

All 187 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 237 Alcoholism studies recruiting now, 84 (35%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 21 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,073 studies in Alcoholism with a site in United States, or all of them as a file.
02

Study summary

H8R-MC-HJAQ is a Phase 2, parallel, double-blind, randomized study comparing LY686017 with placebo in a 12-week trial that includes Medical Management. This study is an outpatient study in which approximately 180 alcohol dependent subjects will be enrolled. Subjects will be randomized in a 1:1 fashion to LY686017 or placebo, and will receive once daily dosing for twelve weeks.

03

Conditions studied

  • Alcohol Dependence

Browse trials for

Keywords

  • Alcoholic
04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have Alcohol Dependence.
  • Are men or women who are ambulatory outpatients between 21 to 65 years of age (inclusive) showing evidence of living in a non-custodial stable residence and with no plans to move during the next 5 months.
  • Females of (not surgically sterilized and between menopause) must test negative for pregnancy at the time of enrollment based on a pregnancy test. They must agree to use a reliable method of during the study and for 2 months following the last dose of study drug.
  • Drink on average more than 14 drinks (women) or 21 drinks (men) per week with at least 2 heavy drinking days per week.
  • Endorse abstinence or reduction in drinking as an interim goal toward abstinence.

Exclusion criteria

Exclusion Criteria:

  • Are investigator site personnel directly affiliated with this study and/or their immediate families.
  • Are Lilly employees.
  • Are currently enrolled in or discontinued within the last 30 days from a clinical trial.
  • Have experienced an acute alcohol withdrawal syndrome within the past 6 months or are currently or during this study at significant risk of suffering an acute alcohol withdrawal syndrome.
  • Have a history of serious head injury, neoplasm or hemorrhage, prior seizure (other than a history of childhood febrile seizure), or other condition that would place the subject at increased risk for seizures.
  • Are taking or have taken anticonvulsant medications for seizures.
  • Are diagnosed with substance dependence or substance abuse other than alcohol, cannabis, nicotine, or caffeine within 12 months prior to first visit.
  • Are receiving medications or intensive behavioral or psychological therapy delivered by a licensed or certified alcohol treatment specialist for alcohol dependence.
  • Have signs and symptoms or an active illness within the past 2 weeks of first visit that meet criteria diagnosis of Major Depressive Disorder. In addition, meet criteria as diagnosis for any comorbid Axis I disorders (such as anxiety disorders, obsessive compulsive disorder (OCD), Posttraumatic stress disorder (PTSD), panic disorder, or dysthymia).
  • Have a positive urine drug screen for any non-prescribed substances of abuse.
  • Have a serious medical illness including but not limited to any cardiovascular, hepatic, respiratory, hematological, endocrine, or neurological disease, or any laboratory abnormality.
  • Ever had electroconvulsive therapy (ECT).
  • Have abnormal thyroid stimulating hormone (TSH) concentrations or are taking thyroid supplements.
  • Have a history of cirrhosis or laboratory evidence of hepatocellular injury.
  • An abnormality in serum .
  • Are unable to make themselves available for the duration of the study or abide by study procedures and restrictions.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
190 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    LY686017

    Drug: LY686017

Interventions

  • 50 milligrams (mg) daily by oral route for 12 weeks

  • DrugPlacebo

    Daily by oral route for 12 weeks

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Heavy Drinking Days

    The Alcohol Timeline Followback (TLFB) is used in calculating the percent reduction in heavy drinking days. The TLFB is a method for assessing the quantity of alcohol consumption on a daily basis. With a calendar as a guide, the interviewee provides a retrospective estimate of daily habits over a specified period of as long as the previous year. The goal is to provide a detailed record of patterns of use that can be used to guide treatment and to assess treatment outcome. Recorded is the number of standard drinks that have been consumed each day during last 4 weeks. One standard drink on the TLFB was defined as: 12 ounce (oz) beer \[5% alcohol by volume (abv)\], 5 oz of wine (10-12% abv), 3 oz of fortified wine (16-18% abv), or 1-1.2 oz of hard liquor (86-100 proof; 43-50% abv). Heavy drinking is defined as ≥4 drinks per day for women and ≥5 drinks per day for men.

    Time frame: Baseline, Weeks 4 and 8 and 12 and 16

Secondary outcomes

  1. Percent Days Abstinent Per Month

    The Alcohol Timeline Followback (TLFB) is used in calculating the percentage of days abstinent (days where no alcoholic drinks were consumed). The TLFB is a method for assessing the quantity of alcohol consumption on a daily basis. With a calendar as a guide, the interviewee provides a retrospective estimate of daily habits over a specified period of as long as the previous year. The goal is to provide a detailed record of patterns of use that can be used to guide treatment and to assess treatment outcome. Recorded is the number of standard drinks that have been consumed each day. One standard drink on the TLFB was defined as: 12 ounce (oz) beer \[5% alcohol by volume (abv)\], 5 oz of wine (10-12% abv), 3 oz of fortified wine (16-18% abv), or 1-1.2 oz of hard liquor (86-100 proof; 43-50% abv). Percentage days per month= (number of days where no alcoholic beverages were consumed/number of days in a month)\*100.

    Time frame: Baseline and Weeks 4 and 8 and 12 and 16.

  2. Number of Drinks Per Drinking Day During a Month

    The Alcohol Timeline Followback (TLFB) is used in calculating the number of drinks per drinking day. The TLFB is a method for assessing the quantity of alcohol consumption on a daily basis. With a calendar as a guide, the interviewee provides a retrospective estimate of daily habits over a specified period of as long as the previous year. The goal is to provide a detailed record of patterns of use that can be used to guide treatment and to assess treatment outcome. Recorded is the number of standard drinks that have been consumed each day. One standard drink on the TLFB was defined as: 12 ounce (oz) beer \[5% alcohol by volume (abv)\], 5 oz of wine (10-12% abv), 3 oz of fortified wine (16-18% abv), or 1-1.2 oz of hard liquor (86-100 proof; 43-50% abv).

    Time frame: Baseline and Weeks 4 and 8 and12 and 16

  3. Time to First Heavy Drinking Day

    The Alcohol Timeline Followback (TLFB) is used to assess the time to first heavy drinking day. The TLFB is a method for assessing the quantity of alcohol consumption on a daily basis. With a calendar as a guide, the interviewee provides a retrospective estimate of daily habits over a specified period of as long as the previous year. The goal is to provide a detailed record of patterns of use that can be used to guide treatment and to assess treatment outcome. Recorded is the number of standard drinks that have been consumed each day. One standard drink on the TLFB was defined as: 12 ounce (oz) beer \[5% alcohol by volume (abv)\], 5 oz of wine (10-12% abv), 3 oz of fortified wine (16-18% abv), or 1-1.2 oz of hard liquor (86-100 proof; 43-50% abv). Heavy drinking is defined as ≥4 drinks per day for women and ≥5 drinks per day for men. Those who did not drink are considered to be "censored."

    Time frame: Baseline up to Week 12

  4. Change From Baseline in Drinker Inventory of Consequences (DrInC) Subscale and Total Scale

    DrInC is a self-administered, 50-item questionnaire designed to measure adverse consequences of alcohol abuse in 5 areas: Interpersonal, Physical, Social, Impulsive, and Intrapersonal. All items for the DrInC are scored from 0-3 with higher scores indicating worse adverse consequences. Interpersonal subscale (10 items: scores range from 0-30) measures the impact of drinking on the participants' relationships. Physical subscale (8 items: scores range from 0-24) measures adverse physical states resulting from excessive drinking. Social subscale (7 items: scores range from 0-21) measures role fulfillment. Impulsive subscale (12 items: scores range from 0-36) measures sequelae of over drinking. Intrapersonal subscale (8 items: scores range from 0-24) measures subjective perceptions that may not be readily observable by others. Total scores range from 0-150, with higher scores indicating greater severity of symptoms.

    Time frame: Baseline, Week 12

  5. Change From Baseline in Alcohol Urge Questionnaire (AUQ)

    AUQ measures participant's feeling and thoughts about drinking, and uses a 7 point (1-7) Likert scale for each of 8 items (questions). Scores range from 8 (less urge to drink) to 56 (more urge to drink).

    Time frame: Baseline, Weeks 1 and 2 and 3 and 4 and 6 and 8 and 10 and 12

  6. Change From Baseline in Penn Alcohol Craving Scale (PACS)

    PACS is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, ability to resist drinking and craving. Each item ranges from 0-6 with 6 indicating worse symptoms.

    Time frame: Baseline, Weeks 1 and 2 and 3 and 4 and 6 and 8 and 10 and 12

  7. Change From Baseline in Beck Depression Inventory II (BDI-II) Total Score

    BDI-II is a 21-item, participant-completed questionnaire to assess characteristics of depression. There is a 4-point scale for each item ranging from 0 (no depression) to 3 (very depressed). Total scores range from 0-63. Higher scores indicate greater severity of depression.

    Time frame: Baseline, Weeks 1 and 2 and 3 and 4 and 6 and 8 and 10 and 12

  8. Change From Baseline Beck Anxiety Index (BAI) Total Score

    BAI is a 21-item participant-completed questionnaire designed to assess the characteristics of anxiety. Each item is rated on a 4-point scale (0= not present; 3= present in the extreme). Total scores range from 0 to 63. Higher total scores indicate greater severity of anxiety symptoms.

    Time frame: Baseline, Weeks 6 and 12

  9. Change From Baseline in Plasma Gamma-Glutamyl Transferase (GGT)

    Time frame: Baseline, Weeks 1 and 2 and 3 and 4 and 6 and 8 and 10 and 12

  10. Change From Baseline in Plasma Carbohydrate Deficient Transferrin (CDT)

    Carbohydrate Deficient Transferrin is a laboratory test that measures alcohol consumption. Greater levels suggest recent alcohol consumption.

    Time frame: Baseline, Weeks 1 and 2 and 3 and 4 and 6 and 8 and 10 and 12

  11. 12 -Item Short-Form Health Survey (SF-12) Scores: Physical Component Summary (PCS)

    Short Form 12 (SF-12) is a 12-item assessment used to measure participant's physical wellbeing \[physical component score (PCS)\] and mental wellbeing \[mental component score (MCS)\]. The PCS score ranges from 0 (lowest wellbeing) to 100 (highest wellbeing) and is designed to have a mean of 50 and standard deviation (SD) of 10 in the general population.

    Time frame: Baseline and Week 12

  12. 12-Item Short-Form Health Survey (SF-12) Scores: Mental Component Summary (MCS)

    Short Form 12 (SF-12) is a 12-item assessment used to measure participant's physical wellbeing \[physical component score (PCS)\] and mental wellbeing \[mental component score (MCS)\]. The MCS score ranges from 0 (lowest wellbeing) to 100 (highest wellbeing) and is designed to have a mean of 50 and standard deviation (SD) of 10 in the general population.

    Time frame: Baseline and Week 12

07

Results

Posted Feb 13, 2018

Participant flow

Participant flow — Overall Study
MilestoneLY686017Placebo
Started9496
Full analysis set (fas)9291
Completed6060
Not completed3436
Withdrew: Adverse event52
Withdrew: Lack of efficacy02
Withdrew: Protocol violation48
Withdrew: Lost to follow-up1013
Withdrew: Withdrawal by subject159
Withdrew: Physician decision01
Withdrew: Acute alcohol withdrawal01

Outcome measures

PrimaryPercent Change From Baseline in Heavy Drinking Days

The Alcohol Timeline Followback (TLFB) is used in calculating the percent reduction in heavy drinking days. The TLFB is a method for assessing the quantity of alcohol consumption on a daily basis. With a calendar as a guide, the interviewee provides a retrospective estimate of daily habits over a specified period of as long as the previous year. The goal is to provide a detailed record of patterns of use that can be used to guide treatment and to assess treatment outcome. Recorded is the number of standard drinks that have been consumed each day during last 4 weeks. One standard drink on the TLFB was defined as: 12 ounce (oz) beer \[5% alcohol by volume (abv)\], 5 oz of wine (10-12% abv), 3 oz of fortified wine (16-18% abv), or 1-1.2 oz of hard liquor (86-100 proof; 43-50% abv). Heavy drinking is defined as ≥4 drinks per day for women and ≥5 drinks per day for men.

Time frame:
Baseline, Weeks 4 and 8 and 12 and 16
Reported as:
Mean · percent of heavy drinking days
Percent Change From Baseline in Heavy Drinking Days
percent of heavy drinking daysLY686017Placebo
Week 4-45.63 ± 36.58-39.72 ± 36.52
Week 8-60.98 ± 39.25-49.88 ± 48.43
Week 12-68.56 ± 40.01-57.44 ± 42.02
Week 16-69.46 ± 35.84-59.12 ± 40.42
SecondaryPercent Days Abstinent Per Month

The Alcohol Timeline Followback (TLFB) is used in calculating the percentage of days abstinent (days where no alcoholic drinks were consumed). The TLFB is a method for assessing the quantity of alcohol consumption on a daily basis. With a calendar as a guide, the interviewee provides a retrospective estimate of daily habits over a specified period of as long as the previous year. The goal is to provide a detailed record of patterns of use that can be used to guide treatment and to assess treatment outcome. Recorded is the number of standard drinks that have been consumed each day. One standard drink on the TLFB was defined as: 12 ounce (oz) beer \[5% alcohol by volume (abv)\], 5 oz of wine (10-12% abv), 3 oz of fortified wine (16-18% abv), or 1-1.2 oz of hard liquor (86-100 proof; 43-50% abv). Percentage days per month= (number of days where no alcoholic beverages were consumed/number of days in a month)\*100.

Time frame:
Baseline and Weeks 4 and 8 and 12 and 16.
Reported as:
Mean · percentage days abstinent per month
Percent Days Abstinent Per Month
percentage days abstinent per monthLY686017Placebo
Baseline11.63 ± 12.5514.54 ± 17.32
Week 430.28 ± 28.1329.44 ± 26.56
Week 840.73 ± 32.9740.07 ± 33.68
Week 1251.43 ± 32.5945.81 ± 34.74
Week 1652.92 ± 32.0744.63 ± 36.84
SecondaryNumber of Drinks Per Drinking Day During a Month

The Alcohol Timeline Followback (TLFB) is used in calculating the number of drinks per drinking day. The TLFB is a method for assessing the quantity of alcohol consumption on a daily basis. With a calendar as a guide, the interviewee provides a retrospective estimate of daily habits over a specified period of as long as the previous year. The goal is to provide a detailed record of patterns of use that can be used to guide treatment and to assess treatment outcome. Recorded is the number of standard drinks that have been consumed each day. One standard drink on the TLFB was defined as: 12 ounce (oz) beer \[5% alcohol by volume (abv)\], 5 oz of wine (10-12% abv), 3 oz of fortified wine (16-18% abv), or 1-1.2 oz of hard liquor (86-100 proof; 43-50% abv).

Time frame:
Baseline and Weeks 4 and 8 and12 and 16
Reported as:
Mean · drinks/drinking day/month
Number of Drinks Per Drinking Day During a Month
drinks/drinking day/monthLY686017Placebo
Baseline7.04 ± 3.077.35 ± 3.78
Week 43.92 ± 2.374.69 ± 3.64
Week 83.03 ± 2.523.36 ± 3.31
Week 122.32 ± 2.252.99 ± 3.70
Week 162.31 ± 2.832.92 ± 3.38
SecondaryTime to First Heavy Drinking Day

The Alcohol Timeline Followback (TLFB) is used to assess the time to first heavy drinking day. The TLFB is a method for assessing the quantity of alcohol consumption on a daily basis. With a calendar as a guide, the interviewee provides a retrospective estimate of daily habits over a specified period of as long as the previous year. The goal is to provide a detailed record of patterns of use that can be used to guide treatment and to assess treatment outcome. Recorded is the number of standard drinks that have been consumed each day. One standard drink on the TLFB was defined as: 12 ounce (oz) beer \[5% alcohol by volume (abv)\], 5 oz of wine (10-12% abv), 3 oz of fortified wine (16-18% abv), or 1-1.2 oz of hard liquor (86-100 proof; 43-50% abv). Heavy drinking is defined as ≥4 drinks per day for women and ≥5 drinks per day for men. Those who did not drink are considered to be "censored."

Time frame:
Baseline up to Week 12
Reported as:
Mean · days
Time to First Heavy Drinking Day
daysLY686017Placebo
Time to First Heavy Drinking Day7.3 ± 16.88.0 ± 22.2
SecondaryChange From Baseline in Drinker Inventory of Consequences (DrInC) Subscale and Total Scale

DrInC is a self-administered, 50-item questionnaire designed to measure adverse consequences of alcohol abuse in 5 areas: Interpersonal, Physical, Social, Impulsive, and Intrapersonal. All items for the DrInC are scored from 0-3 with higher scores indicating worse adverse consequences. Interpersonal subscale (10 items: scores range from 0-30) measures the impact of drinking on the participants' relationships. Physical subscale (8 items: scores range from 0-24) measures adverse physical states resulting from excessive drinking. Social subscale (7 items: scores range from 0-21) measures role fulfillment. Impulsive subscale (12 items: scores range from 0-36) measures sequelae of over drinking. Intrapersonal subscale (8 items: scores range from 0-24) measures subjective perceptions that may not be readily observable by others. Total scores range from 0-150, with higher scores indicating greater severity of symptoms.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Drinker Inventory of Consequences (DrInC) Subscale and Total Scale
units on a scaleLY686017Placebo
Interpersonal-2.9 ± 5.5-3.9 ± 6.8
Physical-3.1 ± 4.0-2.3 ± 4.3
Social-2.0 ± 3.4-2.1 ± 4.1
Impulsive-2.5 ± 4.4-2.5 ± 5.8
Intrapersonal-4.2 ± 6.7-3.7 ± 6.2
Total-16.2 ± 22.2-16.4 ± 25.5
SecondaryChange From Baseline in Alcohol Urge Questionnaire (AUQ)

AUQ measures participant's feeling and thoughts about drinking, and uses a 7 point (1-7) Likert scale for each of 8 items (questions). Scores range from 8 (less urge to drink) to 56 (more urge to drink).

Time frame:
Baseline, Weeks 1 and 2 and 3 and 4 and 6 and 8 and 10 and 12
Reported as:
Mean · units on a scale
Change From Baseline in Alcohol Urge Questionnaire (AUQ)
units on a scaleLY686017Placebo
Week 1-2.9 ± 10.2-2.9 ± 8.8
Week 2-5.0 ± 11.5-3.6 ± 11.1
Week 3-5.3 ± 10.5-6.0 ± 9.6
Week 4-5.9 ± 10.9-5.9 ± 10.1
Week 6-6.4 ± 11.0-8.5 ± 11.7
Week 8-5.8 ± 10.6-7.7 ± 11.8
Week 10-5.7 ± 11.0-7.7 ± 12.7
Week 12-6.3 ± 10.6-9.0 ± 12.5
SecondaryChange From Baseline in Penn Alcohol Craving Scale (PACS)

PACS is a 5-item self-administered instrument that measures frequency, intensity, and duration of thoughts about drinking, ability to resist drinking and craving. Each item ranges from 0-6 with 6 indicating worse symptoms.

Time frame:
Baseline, Weeks 1 and 2 and 3 and 4 and 6 and 8 and 10 and 12
Reported as:
Mean · units on a scale
Change From Baseline in Penn Alcohol Craving Scale (PACS)
units on a scaleLY686017Placebo
Frequency: Week 1-1.0 ± 1.4-0.6 ± 1.3
Frequency: Week 2-1.3 ± 1.4-1.0 ± 1.3
Frequency: Week 3-1.4 ± 1.5-1.0 ± 1.3
Frequency: Week 4-1.5 ± 1.6-1.3 ± 1.3
Frequency: Week 6-1.5 ± 1.6-1.3 ± 1.3
Frequency: Week 8-1.5 ± 1.5-1.3 ± 1.4
Frequency: Week 10-1.7 ± 1.6-1.3 ± 1.3
Frequency: Week 12-1.7 ± 1.5-1.4 ± 1.4
Intensity: Week 1-1.2 ± 1.7-0.7 ± 1.4
Intensity: Week 2-1.6 ± 1.6-1.0 ± 1.3
Intensity: Week 3-1.7 ± 1.7-1.3 ± 1.4
Intensity: Week 4-1.8 ± 1.8-1.4 ± 1.6
Intensity: Week 6-2.0 ± 2.0-1.6 ± 1.7
Intensity: Week 8-2.0 ± 1.8-1.5 ± 1.7
Intensity: Week 10-2.1 ± 1.8-1.6 ± 1.6
Intensity: Week 12-2.2 ± 1.6-1.8 ± 1.7
Duration: Week 1-0.9 ± 1.6-0.4 ± 1.6
Duration: Week 2-1.1 ± 1.7-0.6 ± 1.7
Duration: Week 3-1.2 ± 1.8-0.7 ± 1.5
Duration: Week 4-1.1 ± 1.7-0.8 ± 1.5
Duration: Week 6-1.3 ± 1.9-0.9 ± 1.6
Duration: Week 8-1.2 ± 1.6-1.0 ± 1.8
Duration: Week 10-1.2 ± 1.8-1.0 ± 1.6
Duration: Week 12-1.4 ± 1.8-1.0 ± 1.8
Resistance: Week 1-1.2 ± 1.6-0.9 ± 1.7
Resistance: Week 2-1.4 ± 1.7-1.0 ± 1.8
Resistance: Week 3-1.4 ± 1.8-1.2 ± 1.6
Resistance: Week 4-1.6 ± 1.9-1.3 ± 1.7
Resistance: Week 6-1.6 ± 2.0-1.5 ± 2.0
Resistance: Week 8-1.8 ± 1.9-1.5 ± 1.9
Resistance: Week 10-1.7 ± 1.9-1.5 ± 1.8
Resistance: Week 12-1.9 ± 1.8-1.4 ± 1.8
Craving: Week 1-1.0 ± 1.2-0.6 ± 1.2
Craving: Week 2-1.2 ± 1.3-0.9 ± 1.2
Craving: Week 3-1.4 ± 1.3-1.1 ± 1.2
Craving: Week 4-1.5 ± 1.4-1.2 ± 1.2
Craving: Week 6-1.7 ± 1.4-1.4 ± 1.3
Craving: Week 8-1.7 ± 1.4-1.4 ± 1.3
Craving: Week 10-1.6 ± 1.4-1.4 ± 1.2
Craving: Week 12-1.8 ± 1.4-1.5 ± 1.3
SecondaryChange From Baseline in Beck Depression Inventory II (BDI-II) Total Score

BDI-II is a 21-item, participant-completed questionnaire to assess characteristics of depression. There is a 4-point scale for each item ranging from 0 (no depression) to 3 (very depressed). Total scores range from 0-63. Higher scores indicate greater severity of depression.

Time frame:
Baseline, Weeks 1 and 2 and 3 and 4 and 6 and 8 and 10 and 12
Reported as:
Mean · units on a scale
Change From Baseline in Beck Depression Inventory II (BDI-II) Total Score
units on a scaleLY686017Placebo
Week 10.0 ± 4.1-1.4 ± 3.6
Week 2-0.9 ± 4.1-1.0 ± 3.9
Week 3-1.5 ± 4.7-1.2 ± 3.9
Week 4-1.7 ± 5.7-2.0 ± 4.5
Week 6-0.8 ± 5.8-1.7 ± 5.5
Week 8-1.4 ± 5.3-3.2 ± 5.9
Week 10-1.5 ± 6.3-2.8 ± 6.7
Week 12-2.0 ± 5.9-3.0 ± 6.7
SecondaryChange From Baseline Beck Anxiety Index (BAI) Total Score

BAI is a 21-item participant-completed questionnaire designed to assess the characteristics of anxiety. Each item is rated on a 4-point scale (0= not present; 3= present in the extreme). Total scores range from 0 to 63. Higher total scores indicate greater severity of anxiety symptoms.

Time frame:
Baseline, Weeks 6 and 12
Reported as:
Mean · units on a scale
Change From Baseline Beck Anxiety Index (BAI) Total Score
units on a scaleLY686017Placebo
Week 6-1.9 ± 6.6-2.3 ± 7.2
Week 12-1.3 ± 6.7-2.0 ± 6.8
SecondaryChange From Baseline in Plasma Gamma-Glutamyl Transferase (GGT)
Time frame:
Baseline, Weeks 1 and 2 and 3 and 4 and 6 and 8 and 10 and 12
Reported as:
Mean · units per liter (U/L)
Change From Baseline in Plasma Gamma-Glutamyl Transferase (GGT)
units per liter (U/L)LY686017Placebo
Week 1-5.4 ± 18.8-1.3 ± 9.4
Week 2-6.6 ± 20.2-2.1 ± 12.9
Week 3-9.7 ± 26.1-3.7 ± 13.7
Week 4-8.0 ± 27.3-3.0 ± 14.2
Week 6-10.9 ± 33.4-4.1 ± 17.8
Week 8-10.9 ± 36.2-3.4 ± 20.6
Week 10-12.2 ± 35.8-4.0 ± 26.4
Week 12-11.5 ± 42.6-2.1 ± 20.1
SecondaryChange From Baseline in Plasma Carbohydrate Deficient Transferrin (CDT)

Carbohydrate Deficient Transferrin is a laboratory test that measures alcohol consumption. Greater levels suggest recent alcohol consumption.

Time frame:
Baseline, Weeks 1 and 2 and 3 and 4 and 6 and 8 and 10 and 12
Reported as:
Mean · percent CDT
Change From Baseline in Plasma Carbohydrate Deficient Transferrin (CDT)
percent CDTLY686017Placebo
Week 1-0.1 ± 0.5-0.0 ± 0.7
Week 2-0.2 ± 0.7-0.1 ± 0.8
Week 3-0.1 ± 0.9-0.0 ± 1.2
Week 4-0.2 ± 0.90.1 ± 1.5
Week 6-0.1 ± 1.20.2 ± 1.5
Week 8-0.0 ± 1.40.1 ± 1.3
Week 10-0.1 ± 1.50.1 ± 0.8
Week 12-0.0 ± 1.20.1 ± 0.7
Secondary12 -Item Short-Form Health Survey (SF-12) Scores: Physical Component Summary (PCS)

Short Form 12 (SF-12) is a 12-item assessment used to measure participant's physical wellbeing \[physical component score (PCS)\] and mental wellbeing \[mental component score (MCS)\]. The PCS score ranges from 0 (lowest wellbeing) to 100 (highest wellbeing) and is designed to have a mean of 50 and standard deviation (SD) of 10 in the general population.

Time frame:
Baseline and Week 12
Reported as:
Mean · units on a scale
12 -Item Short-Form Health Survey (SF-12) Scores: Physical Component Summary (PCS)
units on a scaleLY686017Placebo
PCS: Baseline49.2 ± 8.750.2 ± 8.3
PCS: Week 1253.0 ± 8.651.4 ± 7.5
Secondary12-Item Short-Form Health Survey (SF-12) Scores: Mental Component Summary (MCS)

Short Form 12 (SF-12) is a 12-item assessment used to measure participant's physical wellbeing \[physical component score (PCS)\] and mental wellbeing \[mental component score (MCS)\]. The MCS score ranges from 0 (lowest wellbeing) to 100 (highest wellbeing) and is designed to have a mean of 50 and standard deviation (SD) of 10 in the general population.

Time frame:
Baseline and Week 12
Reported as:
Mean · units on a scale
12-Item Short-Form Health Survey (SF-12) Scores: Mental Component Summary (MCS)
units on a scaleLY686017Placebo
MCS: Baseline45.7 ± 11.644.2 ± 11.2
MCS: Week 1248.5 ± 10.049.7 ± 9.6

Adverse events

Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LY686017—0/92 (0%)73/92 (79.3%)
Placebo—0/91 (0%)68/91 (74.7%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventLY686017Placebo
NauseaGastrointestinal disorders7/9214/91
Upper respiratory tract infectionInfections and infestations10/9214/91
HeadacheNervous system disorders6/929/91
Dry mouthGastrointestinal disorders9/926/91
FatigueGeneral disorders8/927/91
DizzinessNervous system disorders7/923/91
SomnolenceNervous system disorders7/920/91
DiarrhoeaGastrointestinal disorders5/923/91
Back painMusculoskeletal and connective tissue disorders5/924/91
InsomniaPsychiatric disorders5/923/91

Baseline characteristics

Full Analysis Set: all randomized participants who received ≥1 dose study drug and contributed to post-baseline data.

Age, Continuous
Age, Continuous(years)LY686017PlaceboTotal
Mean44.3 ± 10.543.0 ± 11.143.7 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)LY686017PlaceboTotal
Female333669
Male5955114
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LY686017PlaceboTotal
Hispanic or Latino6410
Not Hispanic or Latino8687173
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LY686017PlaceboTotal
American Indian or Alaska Native101
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American182139
White6967136
More than one race000
Unknown or Not Reported336
Region of Enrollment
Region of Enrollment(Participants)LY686017PlaceboTotal
United States9291183
08

Study locations

21 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Oceanside, California 92056, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Diego, California 92103, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Deerfield Beach, Florida 33441, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    North Miami, Florida 33161, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Naperville, Illinois 60563, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Indianapolis, Indiana 76260, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lafayette, Indiana 47905, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shreveport, Louisiana 71101, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Boston, Massachusetts 02118, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Albuquerque, New Mexico 87102, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Canton, Ohio 44718, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Oklahoma City, Oklahoma 73103, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Portland, Oregon 97209, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Havertown, Pennsylvania 19083, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nashville, Tennessee 37232, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Austin, Texas 78756, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    DeSoto, Texas 75115, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Houston, Texas 77090, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Charlottesville, Virginia 22908, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kirkland, Washington 98033, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seattle, Washington 98104, United States
09

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2018, 8 years 7 months after primary completion. A results delay was requested in May 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2008
First posted
Dec 9, 2008
Start
Dec 2008
Primary completionActual
Jul 2009
CompletionActual
Jul 2009
Results delay requested
May 27, 2010
Results first posted
Feb 13, 2018
Last update
Sep 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00805441
Responsible party
Sponsor
First posted
Dec 9, 2008
Start date
Dec 2008
Primary completion
Jul 2009
Completion
Jul 2009
Results posted
Feb 13, 2018
Last update
Sep 17, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tradipitant

Start the discussion